Table 1.
The association between RBM15 expression and clinicopathological characteristics of NSCLC patients
| RBM15 High Expression (N = 81) | RBM15 Low Expression (N = 52) | Overall (N = 133) | P | |
|---|---|---|---|---|
| Gender | ||||
| Female | 25 (30.9%) | 12 (23.1%) | 37 (27.8%) | 0.428 |
| Male | 56 (69.1%) | 40 (76.9%) | 96 (72.2%) | |
| Age (year) | ||||
| < 60 | 19(36.5%) | 25(30.9%) | 44(33.1%) | 0.572 |
| > = 60 | 33(63.5%) | 56(69.1%) | 89(66.9%) | |
| Smoke | ||||
| Yes | 49 (60.5%) | 34 (65.4%) | 83 (62.4%) | 0.715 |
| No | 30 (37.0%) | 18 (34.6%) | 48 (36.1%) | |
| Missing | 2 (2.5%) | 0 (0%) | 2 (1.5%) | |
| Alcohol | ||||
| Yes | 24 (29.6%) | 18 (34.6%) | 42 (31.6%) | 0.571 |
| No | 57 (70.4%) | 34 (65.4%) | 91 (68.4%) | |
| Stage | ||||
| II | 1 (1.2%) | 0 (0%) | 1 (0.8%) | 0.578 |
| IIA | 4 (4.9%) | 4 (7.7%) | 8 (6.0%) | |
| IIB | 10 (12.3%) | 8 (15.4%) | 18 (13.5%) | |
| III | 2 (2.5%) | 0 (0%) | 2 (1.5%) | |
| IIIA | 36 (44.4%) | 18 (34.6%) | 54 (40.6%) | |
| IIIB | 23 (28.4%) | 15 (28.8%) | 38 (28.6%) | |
| IIIC | 5 (6.2%) | 7 (13.5%) | 12 (9.0%) | |
| N | ||||
| N0 | 19 (23.5%) | 8 (15.4%) | 27 (20.3%) | 0.379 |
| N1 | 6 (7.4%) | 8 (15.4%) | 14 (10.5%) | |
| N2 | 39 (48.1%) | 24 (46.2%) | 63 (47.4%) | |
| N3 | 17 (21.0%) | 12 (23.1%) | 29 (21.8%) | |
| T | ||||
| T1 | 10 (12.3%) | 8 (15.4%) | 18 (13.5%) | 0.189 |
| T2 | 39 (48.1%) | 23 (44.2%) | 62 (46.6%) | |
| T3 | 9 (11.1%) | 12 (23.1%) | 21 (15.8%) | |
| T4 | 21 (25.9%) | 8 (15.4%) | 29 (21.8%) | |
| Missing | 2 (2.5%) | 1 (1.9%) | 3 (2.3%) | |
| RECIST1.1 | ||||
| CR | 1 (1.2%) | 2 (3.8%) | 3 (2.3%) | < 0.001 |
| PD | 15 (18.5%) | 2 (3.8%) | 17 (12.8%) | |
| PR | 31 (38.3%) | 40 (76.9%) | 71 (53.4%) | |
| SD | 34 (42.0%) | 8 (15.4%) | 42 (31.6%) | |
| Chemotherapy | ||||
| Gemcitabine + Cisplatin | 10 (12.3%) | 14 (26.9%) | 24 (18.0%) | 0.377 |
| Paclitaxel (single agent) | 6 (7.4%) | 3 (5.8%) | 9 (6.8%) | |
| Paclitaxel + Cisplatin | 4 (4.9%) | 4 (7.7%) | 8 (6.0%) | |
| Docetaxel + Carboplatin | 4 (4.9%) | 2 (3.8%) | 6 (4.5%) | |
| Docetaxel + Cisplatin | 4 (4.9%) | 1 (1.9%) | 5 (3.8%) | |
| Others* | 19 (23.5%) | 10 (19.2%) | 29 (21.8%) | |
| NO | 34 (42.0%) | 17 (32.7%) | 51 (38.3%) | |
| Missing | 0 (0%) | 1 (1.9%) | 1 (0.8%) | |
| Radiotherapy | ||||
| Radio sensitivity | 29 (35.8%) | 43 (82.7%) | 72 (54.1%) | < 0.001 |
| Radio resistance | 52 (64.2%) | 9 (17.3%) | 61 (45.9%) | |
*Others Chemotherapy included a total of 16 regimens, such as Docetaxel + Nedaplatin, Paclitaxel + Carboplatin, and Cisplatin + Fluorouracil